<DOC>
	<DOCNO>NCT01299415</DOCNO>
	<brief_summary>This trial design study drug-drug interaction ASA404 fluvoxamine , inhibitor metabolic pathway ( CYP1A2 ) . The study consist two phase . The purpose Core Phase study drug drug interaction fluvoxamine ASA404 . The purpose Extension Phase provide continue treatment patient progress Core Phase collect safety data ASA404 give combination paclitaxel , docetaxel paclitaxel plus carboplatin chemotherapy regimen .</brief_summary>
	<brief_title>Safety Pharmacokinetics ASA404 When Given Together With Fluvoxamine , Selective Serotonin Receptor Reuptake Inhibitor CYP1A2 Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Fluvoxamine</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<criteria>1 . Patients histologicallyproven radiologicallyconfirmed advanced metastatic solid tumor . 2. WHO Performance Status 02 . 3 . A minimum 4 week must elapse since last treatment cancer therapy . 4 . Laboratory value within range , define : ANC ≥ 1.5 X 109 /L Platelets ≥ 100 X 109 /L Hemoglobin ≥ 10 g/dL Serum total bilirubin within normal range 1 . Patients CNS metastasis evidence leptomeningeal disease . 2 . Patients follow : clinical electrocardiographic evidence cadiac ischemia poorly control hypertension family history unexplained sudden death long QT syndrome history ventricular fibrillation torsade de pointes congestive heart failure ( NYHA class III IV ) myocardial infarction within 12 month start study treatment 3 . History neuroendocrine tumor ( e.g . carcinoid tumor , pancreatic islet cell tumor ) . 4 . Significant neurological psychiatric disorder . 5 . Smokers ( use cigarettes within last 3 month ) . 6 . Concomitant use drug associate QTc interval prolongation risk cause torsade de pointes . 7 . Concomitant use serotonin reuptake inhibitor ( SSRIs ) , 5hydroxytryptamine ( 5HT ) receptor agonist selective serotonin / norepinephrine reuptake inhibitor ( SNRIs ) within 30 day prior start study treatment . 8 . Concomitant use somatostain analogue ( i.e . octreotide , lanreotide within 30 day prior start study treatment . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>ASA404 ,</keyword>
	<keyword>Phase I ,</keyword>
	<keyword>Oncology ,</keyword>
	<keyword>CYP1A2 ,</keyword>
	<keyword>fluvoxamine ,</keyword>
	<keyword>drug drug interaction ,</keyword>
	<keyword>Novartis ,</keyword>
	<keyword>Antisoma</keyword>
</DOC>